CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 39 enrolled
Drug / intervention
hCGdrug
Likely dose
hCG 25 microgramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02145247
NCT02145247N/ACompleted
CompareCT.gov

Ovarian Morphology and Theca Cell Androgen Production in Women With Polycystic Ovary Syndrome (PCOS)

University of California, San Diego·interventional·Posted May 22, 2014·Updated Aug 12, 2019

In Brief

A clinical study evaluating hCG for Polycystic Ovary Syndrome. Completed, enrolled 39 participants across 1 site.

Detailed Summary

Women with PCOS suffer from excess male hormone (androgen) production by the ovary. Androgen is made by cells that surround follicles that contain eggs. As the follicles (and eggs) grow and mature, there are more androgen producing cells. Women with PCOS have more follicles than normal women and therefore more androgen producing cells. While androgen production has been associated with the number of follicles, the relationship to the individual size of follicles in PCOS or normal women. This study intends to determine whether the size and number of ovarian follicles are correlated to androgen production in PCOS and normal women.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPolycystic Ovary Syndrome
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMay 22, 2014
Enrollment StartMay 1, 2014
Primary CompletionFeb 1, 2017
Study CompletionJan 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 12.1 years ago

Interventions

hCGdrug

3\. On study day one, recombinant-hCG (r-hCG) will be administered intravenously at a dose of 25 micrograms. 4\. Blood samples will be obtained at T = -0.5, 0, and +24 hours.